Elger W

No ORCID on file · 9 papers in corpus · active 1995-2023

Study types

  • review 5
  • other 2
  • article 1

Condition tags

  • endometriosis 8
  • dysmenorrhea 2
  • dyspareunia 1
article 2023
Next step in the development of mesoprogestins: the preclinical profile of EC313
Frontiers in endocrinology ·doi:10.3389/fendo.2023.1201547

INTRODUCTION: The pharmacological target for progesterone, different progestins, and Selective Progesterone Receptor Modulators (SPRMs) is the nuclear progesterone receptor (PR). EC313 is a new member of a subgroup of SPRMs, mesoprogestins,…

2019
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Human reproduction open ·doi:10.1093/hropen/hoz027

Study questionWhat is the safety and efficacy profile during long-term (12-24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associate…

other 2013
Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins
Steroids ·doi:10.1016/j.steroids.2012.09.010

A series of antiprogestins have been synthesized by partially fluorinating the steroid molecule in positions relevant for receptor binding. By introducing fluorine at the exo-methylene of the 17 spirofuran ring, we obtained partial agonists…

review 2006
Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)
Reproductive biology and endocrinology : RB&E ·doi:10.1186/1477-7827-4-s1-s8

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands that exert clinically relevant tissue-selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist effects on vari…

review 2005
Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs)
Seminars in reproductive medicine ·doi:10.1055/s-2005-864034

Asoprisnil (J 867; benzaldehyde, 4-[(11beta, 17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4, 9-dien-11beta-yl]-, 1-oxime) is the prototype of a novel class 11beta-benzaldoxime-substituted selective progesterone receptor modulators (SPRM…

review 2005
Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis
Endocrine reviews ·doi:10.1210/er.2005-0001

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands. SPRMs exert clinically relevant tissue-selective progesterone agonist, antagonist, or mixed agonist/antagonist effects on various pro…

review 2003
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
Steroids ·doi:10.1016/j.steroids.2003.09.008

Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and structurally related compounds represent a new class of progesteron…

review 2002
Selective Progesterone Receptor Modulators (SPRMs)
Annals of the New York Academy of Sciences ·doi:10.1111/j.1749-6632.2002.tb02798.x

Endometriosis, the presence of endometrial tissue outside the uterus, is a progressive, estrogen-dependent disease and occurs nearly exclusively in menstruating women of reproductive age. Pain syndrome, however, represents the major clinica…

other 1995
Inhibition of aromatase activity in human placental microsomes by 13-retro-antiprogestins
Steroids ·doi:10.1016/0039-128x(94)00043-c

Mifepristone (RU 486), used clinically for the termination of early pregnancy, and its acetyl and 13-retro (13 alpha) analogs show potent antiproliferative effects against estrogen-dependent human breast tumors and endometriosis. However, t…